.jpg?format=webp&width=780)
Previously, found that telaprevir (Tel), the inhibitor of hepatitis C virus NS3/4A serine protease, reduces estrogen receptor α (ERα) content at the transcriptional level without binding to the receptor, prevents ERα transcriptional activity and inhibits basal and 17β‐estradiol (E2)‐dependent cell proliferation in different breast cancer (BC) cell lines. Here, the study further characterize the Tel action mechanisms on ERα levels and function, identify a possible molecular target of Tel in BC cells and evaluate Tel as an antiproliferative agent for BC treatment. Thus, the study propose that this antiviral could be repurposed for the treatment of ERα‐expressing BC.
Like
Save
Share